473 related articles for article (PubMed ID: 37482612)
1. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
4. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
Ma C; Li F; Gu Z; Yang Y; Qi Y
Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
[No Abstract] [Full Text] [Related]
5. Crosstalk between copper homeostasis and cuproptosis reveals a lncRNA signature to prognosis prediction, immunotherapy personalization, and agent selection for patients with lung adenocarcinoma.
Ma C; Gu Z; Ding W; Li F; Yang Y
Aging (Albany NY); 2023 Nov; 15(22):13504-13541. PubMed ID: 38011277
[TBL] [Abstract][Full Text] [Related]
6. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
7. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.
Zhang N; Yu X; Sun H; Zhao Y; Wu J; Liu G
Medicine (Baltimore); 2023 Oct; 102(42):e35167. PubMed ID: 37861553
[TBL] [Abstract][Full Text] [Related]
8. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
9. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
10. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction.
Li L; Cai Q; Wu Z; Li X; Zhou W; Lu L; Yi B; Chang R; Zhang H; Cheng Y; Zhang C; Zhang J
Sci Rep; 2023 Feb; 13(1):2455. PubMed ID: 36774446
[TBL] [Abstract][Full Text] [Related]
12. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
13. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
[TBL] [Abstract][Full Text] [Related]
15. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
Wang X; Jing H; Li H
Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
[TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs.
Tu H; Zhang Q; Xue L; Bao J
Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481
[TBL] [Abstract][Full Text] [Related]
17. A ferroptosis-related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study.
Dong J; Tao T; Yu J; Shan H; Liu Z; Zheng G; Li Z; Situ W; Zhu X; Li Z
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1925. PubMed ID: 38043920
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
20. Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma.
Wang Z; Yao J; Dong T; Niu X
J Immunol Res; 2022; 2022():2756611. PubMed ID: 36281357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
